Key result
Dapagliflozin reduces retinal vascular permeability and preserves adiponectin in early diabetic retinopathy.
Why the study?
The role of adiponectin in the development of diabetic microvascular complications such as diabetic retinopathy is not well understood.
Does adiponectin protect against early retinal vascular damage in a diabetic mouse model?
Does adiponectin protect against early retinal vascular damage in a diabetic mouse model?
Adiponectin may play a protective role against early diabetic retinopathy by preserving retinal endothelial function, an effect that can be supported by dapagliflozin treatment.
Answers are grounded in this paper and cite their sources.
May support adiponectin as a retinal protective target in diabetes; leaves open translation to human diabetic retinopathy.
Adiponectin (APN), a protein abundantly secreted from adipocytes, has been reported to possess beneficial effects on cardiovascular diseases in association with its accumulation on target organs and cells by binding to T-cadherin. However, little is known about the role of APN in the development of diabetic microvascular complications, such as diabetic retinopathy (DR). Here we investigated the impact of APN on the progression of early retinal vascular damage using a streptozotocin (STZ)-induced diabetic mouse model. Our immunofluorescence results clearly showed T-cadherin-dependent localization of APN in the vascular endothelium of retinal arterioles, which was progressively decreased during the course of diabetes. Such reduction of retinal APN accompanied the early features of DR, represented by increased vascular permeability, and was prevented by glucose-lowering therapy with dapagliflozin, a selective sodium-glucose co-transporter 2 inhibitor. In addition, APN deficiency resulted in severe vascular permeability under relatively short-term hyperglycemia, together with a significant increase in vascular cellular adhesion molecule-1 (VCAM-1) and a reduction in claudin-5 in the retinal endothelium. The present study demonstrated a possible protective role of APN against the development of DR.
No takes yet. Share an insight, caveat, or question.
Sakaue et al. (2022) studied Diabetic retinopathy. Dapagliflozin vs. Vehicle was evaluated on Retinal vascular permeability (extravascular Hoechst-positive area) (p=<0.01). Glucose-lowering therapy with dapagliflozin prevented the reduction of retinal adiponectin and significantly reduced retinal vascular permeability in a mouse model of early diabetic retinopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: